Inve India ▾

Kopran share price & results

Kopran Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q3 FY25
Ownership as of
Sept 2026

Integrated pharma maker of export-oriented Finished Dosage Forms and APIs (Atenolol, sterile Carbapenems, Cephalosporins, Macrolides) via Kopran Limited and its API subsidiary Kopran Research Laboratories.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue154 ₹ crore+13.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin10.3 %−0.2 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit6.7 ₹ crore−10.1% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity4.77 %−2.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin0.00 %+2.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)11.96 %+5.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 targets tracked, none judged yet · 5 open · verdicts reflect calls analysed to Q3 FY25.

Kopran Limited management guidance track record on Inve: 5 targets tracked across analysed earnings calls (0 achieved, 0 missed, 5 open).

TargetOriginal wordingSaidLatest callVerdict
EBITDA MarginEBITDA margin is around 28% to 30%
Call transcript, Q3 FY25 · 25 Mar 2025		Q3 FY25Q3 FY25:Management established 28-30% as the target operating margin for the Labs business.
Call transcript, Q3 FY25 · 25 Mar 2025		New

Source: Inve Guidance Tracker for Kopran Limited · to Q3 FY25

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Kopran Limited's 5 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 4 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹249.3 +0.04% · +₹0.1

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +46.7% 1Y

₹100₹150₹200₹250₹300Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹169.89 on 24 Oct 2025 → ₹249.3. High ₹290.9 (29 Sept 2026), low ₹108.04 (30 Mar 2026).

Previous close
₹249.2
Market cap
₹1.2k Cr
52-week range
₹108.04 – ₹290.9
One year
+49.72%
Price to earnings (TTM to Jun 2026)
48.18×
Return on equity (TTM to Jun 2026)
4.77%

Overview

Symbol
NSE:KOPRAN
Exchange
NSE
Currency
INR

What Kopran Limited does

Based on the company's own presentations, annual report and earnings calls.

Kopran Limited, established in 1958, is an integrated pharmaceutical company engaged in the development, manufacturing and global supply of Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). Its formulations vertical (run directly by Kopran Limited) makes Penicillin-based and Non-Penicillin-based oral solid dosage forms — tablets, capsules, dry powder and suspensions — that are 100% export-oriented to regulated and non-regulated markets. Its API vertical, operated through wholly-owned subsidiary Kopran Research Laboratories Limited (KRLL), develops and manufactures APIs and advanced intermediates (including Atenolol, sterile Carbapenems, Cephalosporins and Macrolides) for both export and domestic customers. A Scheme of Amalgamation to merge a separate group entity, Kopran Laboratories Limited (which markets diagnostic equipment, consumables and automation products to path labs and hospitals), into Kopran Limited has been Board-approved and is pending NCLT sanction.

Segments

  • Formulations (Kopran Limited)
  • APIs (Kopran Research Laboratories Ltd, wholly-owned subsidiary)
Manufacturing/R&D sites
3 (Formulation unit – Khopoli, Maharashtra; API unit – Mahad, Maharashtra; API/R&D unit – Panoli, Gujarat, under construction)
API products commercialised (Mahad facility)
26
Formulation dosage forms manufactured
100+ (Tablets, Capsules, Dry Powder, Suspension)
Formulations export footprint
60+ countries (100% export-oriented)
Formulation regulatory approvals
15 countries incl. MHRA (UK), SAHPRA (South Africa), Health Canada, FDA Philippines, TMDA Tanzania
API regulatory accreditations
US FDA, EU GMP, WHO GMP, ANVISA
Founded 1958Headquarters Mumbai, Maharashtra, India Company website

Your own record

Start an Inve Case for Kopran Limited

Free account: one company. Everything above stays public.

Write why you follow Kopran Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Kopran Limited

Guides on how to read this kind of business and the numbers that matter.